Regencell Bioscience Holdings Limited (NASDAQ:RGC) (the "Company"), today announced that its board of directors approved a 38-for-one forward stock split to be paid in the form of a stock bonus. Each shareholder of the Company of record at the close of business on June 12, 2025 will receive 37 additional shares for every share held on the record date. The Company expects the additional shares will be distributed on June 13, 2025. Subject to the final approval by the Nasdaq Capital Market, trading is expected to begin on a post-stock split adjusted basis at market open on June 16, 2025.

The forward stock split is intended to enhance liquidity in the market for the Company's ordinary shares and make the shares more accessible to investors.

Following the split, the Company's outstanding shares will be increased at the ratio of the forward stock split. The Company's authorized share capital and the share par value will remain unchanged.

There will be no change to the Company's name, CUSIP or its current trading symbol in connection with the forward stock split.

No action is required by shareholders in connection with the forward stock split. Shareholders who hold their shares through a brokerage account will have their shares automatically adjusted to reflect the forward stock split. Registered shareholders will receive their additional shares through the Company's transfer agent.